)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
IDEAYA Biosciences
IDEAYA Biosciences (IDYA) investor relations material
IDEAYA Biosciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 collaboration revenue was $10.242M; net loss was $125.749M, versus $119.2M net income in Q3 2025, as operating expenses increased.
Darovasertib plus crizotinib mUM NDA was submitted under FDA’s RTOR program; quarter-end cash, cash equivalents and marketable securities totaled $1.15B.
Financial highlights
Q3 collaboration revenue was $10.242M vs. $8.9M in Q2; R&D expense was $121.6M vs. $108.7M and G&A was $26.3M vs. $22.5M.
Nine-month collaboration revenue was $25.7M vs. $207.8M in 2025, reflecting prior-year Servier upfront license revenue; R&D was $326.0M and G&A was $68.1M.
Q3 operating loss was $137.632M and net loss $125.749M, vs. $122.3M and $112.5M in Q2; nine-month net loss was $336.7M vs. $30.4M in 2025.
Nine-month operating loss was $368.5M vs. $64.7M in 2025; R&D and G&A expenses rose 43% and 53% year over year, respectively.
Outlook and guidance
Cash runway guidance into 2030 remains unchanged under the current operating plan; financial statements also state available liquidity is expected to fund planned operations for at least 12 months from report issuance.
Initial global IDE849 Phase 1/2 data are targeted by year-end 2026 or early 2027; two Phase 3 trials in ES-SCLC and NEC are planned to start by year-end 2026, subject to development progress.
IDE397 expansion is planned for H1 2027, initially focused on MTAP-deleted NSCLC; IDE034 initial Phase 1 data are targeted for 2027.
IDE892 plus RG6505 trial initiation in MTAP-deleted, RAS-mutant PDAC is targeted by year-end 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from IDEAYA Biosciences
- Darovasertib nears NDA, while DLL3 ADC and MTAP/KRAS programs drive pipeline innovation.IDYA
Morgan Stanley 24th Annual Global Healthcare Conference - NDA submission and commercial launch for a late-stage oncology asset are on track; key data updates expected this year.IDYACitigroup’s Biopharma Back to School Summit 2026
- Darovasertib NDA nears completion as pipeline expands with DLL3 ADC, PRMT5, and Roche collaborations.IDYA12th Annual Cantor Fitzgerald Global Healthcare Conference
- Darovasertib and DLL3 programs advance toward key regulatory and clinical milestones.IDYAWells Fargo 21st Annual Healthcare Conference
- Precision oncology pipeline delivers clinical advances in UM and solid tumors, with strong cash runway.IDYACorporate presentation
- Net loss widened to $211M in H1 2026 as R&D spending rose, with $1.24B in cash reserves.IDYAQ2 2026
- Precision oncology pipeline delivers strong clinical results and growth, led by darovasertib in UM.IDYACorporate presentation
- Strong clinical data and AI-driven innovation propel a robust precision oncology pipeline.IDYAR&D Day 2025
- Transformational year ahead with key Darovasertib data, pipeline expansion, and commercialization focus.IDYARBC Capital Markets Global Healthcare Conference 2025
Next IDEAYA Biosciences earnings date
UBS Global Biopharma Conference 202616 Nov, 2026
IDEAYA Biosciences
Next IDEAYA Biosciences earnings date
UBS Global Biopharma Conference 202616 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
IDEAYA Biosciences Inc. is a clinical-stage biotechnology firm primarily engaged in the discovery and development of precision medicine therapeutics for cancer patients. The company's research focuses on synthetic lethality, an innovative class of precision medicine targets, aiming to produce therapeutics that are first-in-class and/or best-in-class. IDEAYA Biosciences leverages molecular diagnostics to select patient populations for its targeted therapies, emphasizing an integrated approach to the discovery and development of biomarkers and therapeutics. This approach spans early discovery through clinical development, targeting unmet needs in cancer treatment. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.